MedTrace Logo

Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization

NCT00317512 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2008-05-16

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and feasibility of a novel oxygen carrying solution, HBOC-201, in the setting of PCI for Acute Coronary Syndromes from randomization til hospital discharge.

Conditions

Interventions

PROCEDURE

Percutaneous Coronary Revascularization

DRUG

Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)

DRUG

Voluven

Sponsors & Collaborators

  • Biopure Corporation

    lead INDUSTRY

Principal Investigators

  • P W Serruys, Professor · University Medical Center Rotterdam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2005-04-30
Completion
2007-07-31

Countries

  • Belgium
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317512 on ClinicalTrials.gov